F-1: Nasus Pharma Files for IPO to Fund Intranasal Epinephrine Development Amidst Going Concern Doubts

Nasus Pharma, a clinical-stage specialty pharmaceutical company, is seeking to raise $9.3 million through an initial public offering to advance its intranasal Epinephrine program, despite significant accumulated losses and ongoing concerns about its ability to continue as a going concern.

Summary

• Nasus Pharma is a clinical-stage specialty pharmaceutical company focused on developing intranasal drugs for emergency medical conditions using its unique Powder-Based Intranasal (PBI) technology.
• The lead product candidate, NS002 (Intranasal Epinephrine) for severe allergies and anaphylaxis, is currently in Phase 2 clinical development.
• NS001 (Intranasal Naloxone) for opioid overdose has completed a pivotal Phase 3 study, but its development has been paused to pursue partnering opportunities.
• Initial clinical trials for both NS002 and NS001 demonstrated quicker and higher drug absorption compared to similar liquid-based nasal products and intramuscular injections.
• The company reported an accumulated deficit of $12.7 million as of December 31, 2024, and a net loss of $1.532 million for 2024, an increase from $1.051 million in 2023.
• Cash and cash equivalents stood at $0.284 million as of December 31, 2024, with current cash expected to fund operations only through September 2025.
• The company is seeking to raise approximately $9.3 million in net proceeds from the IPO, with $6 million to $7 million allocated for NS002 development, including manufacturing scale-up and additional Phase 2 studies.
• Nasus Pharma has applied to list its Ordinary Shares on the NYSE American LLC under the symbol NSRX.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2023, and have not yet been remediated.

Sentiment

Score: 4

Explanation: While the company presents promising preclinical and early-stage clinical data for its PBI technology and identifies large market opportunities, the significant accumulated losses, ongoing 'going concern' doubt, identified material weaknesses in internal controls, and the pausing of NS001 development despite a completed Phase 3 study, indicate substantial financial and operational challenges. The IPO is critical for continued development, but even its proceeds are not expected to be sufficient for full commercialization, necessitating further capital raises. The unresolved Aptar dispute also adds a layer of uncertainty.

Positives

• Unique Powder-Based Intranasal (PBI) technology demonstrated quicker and higher drug absorption over similar solution-based nasal products in initial clinical trials.
• NS002 (Intranasal Epinephrine) pilot study showed significantly higher drug levels in plasma and a three times shorter median time to clinical threshold (100pg/ml) compared to IM EpiPen for the 3.2mg dosage under allergenic challenge.
• NS002 Phase 2 study (NP006) indicated immediate absorption of Epinephrine and quicker, higher peak plasma levels compared to IM Epinephrine injections, achieving statistical significance after four minutes.
• NS002 4mg dosage achieved the clinical threshold level in plasma (100 pg/ml) in 91% of patients compared to 55% of patients receiving EpiPen in a Phase 2 study.
• NS002 demonstrated complete stability of its powder formulation over 2-5 years, unlike liquid-based Epinephrine products which showed significant enantiomeric conversion.
• NS001 (Intranasal Naloxone) pilot and pivotal Phase 3 studies showed significantly faster absorption rates in the immediate critical period after administration compared to Narcan, with higher peak systemic exposure (1.6-fold higher) and earlier Tmax (5 minutes earlier).
• The PBI platform technology can be incorporated into other products, with preclinical/in vitro testing on Midazolam, Atropine, and Ondansetron showing feasibility.
• Prior successful scalability and technology transfer to a European GMP FDA approved manufacturing facility for Naloxone is expected to be leveraged for NS002.
• Maintains a strong intellectual property position with multiple granted patents and pending applications worldwide for dry powder formulations and Epinephrine-specific formulations.
• Has a collaboration agreement with Aptar, a leading global manufacturer of inhalers, for the UDS delivery system.
• Possesses an experienced leadership and executive team with over two decades of experience in the biotechnology industry.

Negatives

• No revenues generated from existing products to date, with significant accumulated operating losses of $12.7 million as of December 31, 2024.
• Net loss increased by 31% from $1.051 million in 2023 to $1.532 million in 2024.
• Current cash and cash equivalents of $0.284 million are insufficient to fund projected operating requirements, raising substantial doubt about the ability to continue as a going concern.
• Identified material weaknesses in internal control over financial reporting as of December 31, 2023, which have not yet been remediated.
• Clinical trials for product candidates are in various stages of development, and the process is lengthy, expensive, and uncertain, with no assurance of regulatory approval or commercial viability.
• NS002 pilot and Phase 2 studies were not powered for statistical significance, meaning observed effects may not be accurate due to small sample size.
• Development of NS001 (Intranasal Naloxone) has been paused, and the company plans to pursue partnering opportunities, indicating a potential delay or shift in focus for this product.
• Relies on a limited number of, or single, suppliers for laboratory instruments and materials (e.g., Aptar for UDS), posing risks of delay, price increases, or unavailability.
• Aptar issued a termination notice in October 2022 for alleged breach of contractual obligations and outstanding payments of $1 million, including termination fees of $450,000 for the Naloxone SOW, which remains unresolved.
• Has limited manufacturing experience and no current commercial-scale manufacturing facilities, relying on third-party manufacturers.
• Future funding requirements are substantial ($18 million to $22 million estimated to fully execute business plan) and additional financing may not be available on acceptable terms, or at all, leading to potential delays or termination of development efforts.
• Faces intense competition in the pharmaceutical industry from companies with significantly greater resources, brand recognition, and experience.
• The market price of Ordinary Shares may be highly volatile due to various factors, including clinical trial results, regulatory approvals, competition, and economic conditions.
• Existing shareholders and management will retain significant influence (72% post-IPO), potentially limiting other shareholders' influence.
• Management will have broad discretion over the use of IPO proceeds.
• Is exposed to fluctuations in currency exchange rates (NIS, Euro vs. USD).
• Potential political, economic, and military instability in Israel could adversely affect operations.
• Management team has limited experience managing a U.S. reporting company.
• Faces risk of security breaches, including cybersecurity incidents, affecting sensitive data and operations.
• Has not paid, and does not intend to pay, dividends on its Ordinary Shares in the foreseeable future.

Risks

• Inability to achieve or maintain profitability due to significant operating losses and lack of revenue from product candidates.
• Substantial doubt about the ability to continue as a going concern due to insufficient cash on hand to fund projected operating requirements.
• Material weaknesses identified in internal control over financial reporting as of December 31, 2023, which could lead to inaccurate financial reporting or fraud if not remediated.
• Uncertainty and length of clinical drug development process, with potential for prolonged delays, suspensions, or failure to obtain regulatory approval.
• Risk that preliminary clinical trial results (e.g., NS002 pilot/Phase 2 with small sample sizes) may not be indicative of future results or sufficient for regulatory approvals.
• Potential for product candidates (NS002, NS001) to lack sufficient efficacy or cause undesirable side effects not previously identified, leading to delayed/prevented approval or commercialization.
• Reliance on third-party manufacturers for Epinephrine and other formulations, posing risks of delay, price increases, or unavailability.
• Reliance on a single supplier (Aptar) for the UDS delivery system, with an unresolved contractual dispute and potential for significant delays if the MSA is terminated.
• Limited manufacturing experience and reliance on third-party manufacturers for commercial-scale production, risking delays or supply problems.
• Uncertainty regarding patent applications resulting in issued patents and the scope of intellectual property protection.
• Risk of competitors using similar product candidates for other uses if patent protection is primarily method-of-use.
• Inability to enforce intellectual property rights globally due to varying laws and costs.
• Dependence on retaining key executives and attracting/retaining qualified personnel, with intense competition for talent.
• Intense competition from larger, more resourced pharmaceutical companies, potentially limiting market acceptance and sales.
• Need to significantly increase organizational size and manage growth effectively.
• Exposure to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy/security laws, with potential for substantial penalties for non-compliance.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies could harm business.
• Changes in regulatory requirements or guidance (e.g., FDA, EMA) could increase costs or delay development/approval.
• Potential for security breaches, including cybersecurity incidents, affecting systems and data.
• Volatility in the market price of Ordinary Shares post-IPO.
• Sales of substantial numbers of shares by existing shareholders post-lock-up could depress share price.
• Raising additional capital would cause dilution to existing shareholders.
• Significant influence of principal shareholders and management (72% post-IPO) over shareholder approval matters.
• Broad discretion of management over IPO proceeds.
• Potential political, economic, and military instability in Israel, where operations are located, could adversely affect business.
• Exposure to currency exchange rate fluctuations (NIS, Euro vs. USD).
• Risk of termination or reduction of Israeli government tax and other incentives.
• Potential requirement to pay monetary remuneration to Israeli employees for inventions.
• Difficulty enforcing non-compete covenants under Israeli law.
• Israeli corporate law provisions may delay or prevent mergers/acquisitions.
• Difficulty enforcing U.S. court judgments in Israel.
• Rights and responsibilities of shareholders governed by Israeli laws, which differ from U.S. laws.
• JOBS Act exemptions may make shares less attractive to some investors.

Future Outlook

The company intends to use IPO proceeds primarily for the development of its Intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies. It plans to initiate two additional Phase 2 studies for NS002 in Q4 2025, followed by an IND submission in Q3 2026, a pivotal Phase 3 study in Q3 2026, and a pediatric study in Q4 2026. The NDA dossier submission for NS002 is targeted for Q2 2027. For NS001, the company has paused development and plans to pursue partnering opportunities. It also continues to explore other potential indications for its PBI technology, including Intranasal Midazolam, Intranasal Atropine, and Intranasal Ondansetron. The company expects to continue incurring significant losses and negative cash flows until its products reach profitability and will require substantial additional funding beyond the IPO proceeds to commercialize its product candidates.

Management Comments

• Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active PBI specialized products.
• We believe that PBI may be superior over liquid-based solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity, thus creating a larger absorption area and enabling more rapid and higher drug absorption.
• We currently intend to focus our development and regulatory approval efforts on our Intranasal Epinephrine and other preclinical programs and plan to pursue partnering opportunities for further development of NS001.
• We expect that we will need to raise substantial additional funding in the future.
• Management expects us to continue to generate substantial operating losses and to continue to fund our operations primarily through the utilization of our current financial resources, and through additional raises of capital.
• Management plans to seek additional equity financing through private and public offerings or strategic partnerships and, in the longer term, by generating revenues from product sales.
• We believe that our cost structure enables us to compete in the market and maintain extremely high margins.
• We believe that our powder intranasal technology showed consistent advantage, including quicker and higher absorption, over the current market leader in intranasal Naloxone.
• Our strategic objective is to develop and commercialize our PBI products. We intend to further advance our breakthrough technologies and commercialization efforts.

Industry Context

The filing highlights the growing intranasal drug delivery market, estimated at $59 billion in 2022 and projected to reach $93.7 billion by 2029, with the U.S. and Europe being major markets. It emphasizes the unmet need for convenient, rapid, and stable drug delivery in emergency situations like anaphylaxis and opioid overdose, where current injectable or liquid-based nasal solutions have limitations such as needle fear, stability issues, and insufficient plasma levels. The company positions its PBI technology as a superior alternative due to potentially higher dispersion and faster absorption, aiming to address these gaps. The document also notes intense competition from major pharmaceutical companies in both Epinephrine and Naloxone markets, including established players like ADAPT Pharma (Narcan), Teva Pharmaceuticals Ltd., Pfizer Inc., Viatris Inc., and Kalo, Inc., as well as other developers of alternative administration routes like ARS Pharmaceuticals, Bryn Pharma, Orexo, and Aquestive Therapeutics.

Comparison to Industry Standards

• NS002 (Intranasal Epinephrine) showed a three times shorter median time to clinical plasma threshold (100pg/ml) compared to IM EpiPen (reference device) in a pilot study (3.2mg dosage under allergenic challenge).
• NS002 4mg achieved the clinical threshold level in plasma (100 pg/ml) in 91% of patients compared to 55% of patients receiving EpiPen in a Phase 2 study.
• NS002 demonstrated immediate absorption and quicker, higher peak plasma Epinephrine levels compared to IM Epinephrine injections in Phase 2.
• NS002 showed complete stability of its powder formulation over 2-5 years, unlike liquid-based Epinephrine products (e.g., EpiPen) which showed high levels of inactive enantiomers and stability issues.
• NS001 (Intranasal Naloxone) pilot study showed a significantly faster absorption rate in the immediate critical period (7-fold higher partial AUC0-4 minutes, 4-fold higher partial AUC0-10 minutes) and higher peak systemic exposure (1.6-fold higher) compared to Narcan (4mg).
• NS001 pivotal Phase 3 study consistently showed an advantage in the first 30 minutes after administration compared to Narcan.
• The company's PBI technology is stated to be superior to liquid-based solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity, creating a larger absorption area and enabling more rapid and higher drug absorption, a phenomenon supported by internal clinical studies and external literature (Djupesland 2013, Williams et al. 2021).
• The company's powder morphology is depicted as uniform and spherical, contrasting with irregular sizes and uncontrolled particles of some third-party formulations used in the pharmaceutical industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that are likely to have a material adverse effect on its business.
• A supplier associated with the Taffix business commenced legal proceedings in May 2022 for $92,000 in professional fees; a liability of $92,000 is recorded as current liabilities related to discontinued operations.
• Aptar Group Inc. sent a termination notice on October 5, 2022, for alleged breach of contractual obligations and outstanding payments of $1 million (including $450,000 termination fees for Naloxone SOW); the company contested this, and no further notices or claims have been received from Aptar since February 2023. The company believes it is not probable it will be required to pay the $900,000 termination fees.

Related Party Transactions

• Services agreements with executive officers (Dan Teleman, Udi Gilboa, Dalia Megiddo, Tair Lapidot, Oren Elmaliach) containing customary provisions regarding noncompetition, confidentiality, and assignment of inventions.
• Indemnification agreements have been entered into with all directors and senior management.
• Share options have been granted to officers and directors under the 2019 Incentive Option Plan.
• The July 2022 Loan of $500,000 from Dr. Ronnie Hershman (director/shareholder) and Michael Gibber (shareholder) was converted into 2024 SAFEs on August 28, 2024.
• The February 2023 Loan of $60,000 from Dr. Ronnie Hershman, Dr. Dalia Megiddo (co-founder/director), and Mr. Udi Gilboa (co-founder/Executive Chairman) was converted into 2024 SAFEs on August 28, 2024.
• Formulex License Agreement (May 2019): Exclusive license for dry powder compositions for intranasal delivery from Formulex Pharma Innovations Ltd., a company owned by co-founders Mr. Ehud Gilboa, Dr. Dalia Megiddo, and director Dr. Ronnie Hershman. Royalties are 0.5% of net sales, capped at $100,000.
• Formulex Service Agreement (June 2019, amended March 2020): Formulex provides chemical manufacturing and controls services for $5,000 per month. Additional development services were provided in 2023 ($22,000) and 2022 ($11,000).
• Formulex Subcontractor Agreement (December 5, 2024): Formulex to provide subcontractor services for potential tenders, with a maximum aggregate consideration of $800,000. $116,000 was paid in 2024 for future services.
• Secretarial Services Agreement (June 1, 2019) with Topnotch Consultancy (2009) Ltd., a company owned by Mr. Udi Gilboa, for $1,373 per month, increased to $4,119 per month in December 2024.
• Property Lease and Office Services Agreement (June 1, 2019) with Topnotch for $3,295 per month.
• 2022 SAFEs ($966,000 aggregate) included participation from co-founders Mr. Gilboa ($35,000), Dr. Megiddo ($35,000), Dr. Ronnie Hershman ($150,000), and Formulex ($30,000). These converted to Class A-3A Ordinary Shares on August 28, 2024.
• 2023 SAFEs ($995,000 aggregate) included participation from Dr. Hershman ($100,000) and his relative Gabriel Hershman ($25,000). These converted to Class A-3B Ordinary Shares on August 28, 2024.
• 2024 SAFEs ($1,986,500 aggregate, with $300,000 canceled) included participation from co-founders Mr. Gilboa ($60,963), Dr. Megiddo ($61,286), and Dr. Hershman ($478,108).
• Related party balances as of December 31, 2024, include $116,000 in prepaid expenses and other current assets, $605,000 in convertible securities, and $711,000 in accrued expense and other current liabilities, all to related parties.
• Related party transactions in 2024 included $208,000 in R&D expenses, $307,000 in G&A expenses, and $17,000 in interest expense.

Stakeholder Impact

• Shareholders face potential for significant dilution from the IPO and future capital raises, high volatility of share price, and the significant influence of existing principal shareholders and management. There is a risk of complete loss of investment due to going concern doubts and development risks, but also potential for long-term value if products achieve commercial success.
• Employees will continue their employment and may receive equity-based compensation, but face the risk of workforce reductions if funding is insufficient or product development fails. Their employment is subject to Israeli labor laws.
• Customers and patients could benefit from new, user-friendly, and effective intranasal treatments for emergency conditions like anaphylaxis and opioid overdose, provided product candidates receive regulatory approval and are commercialized.
• Suppliers and creditors face the risk of payment delays or non-payment if the company's going concern issues are not resolved. Key suppliers like Aptar are critical to the company's operations.
• Regulatory bodies (e.g., FDA, EMA) will continue to oversee the company's clinical development, manufacturing, and marketing activities, with compliance being crucial for product approval and commercialization.

Next Steps

• Complete manufacturing scale-up and tech transfer for NS002 (expected Q3 2025).
• Initiate two additional Phase 2 studies for NS002 (expected Q4 2025).
• Conduct preclinical studies (short animal safety studies in two species) for NS002.
• Conduct stability testing, reliability study, and usability study for NS002.
• Submit IND for NS002 (planned Q3 2026).
• Initiate pivotal Phase 3 study for NS002, including self-administration subsection (intended Q3 2026).
• Initiate pediatric study for NS002 (intended Q4 2026).
• Submit NDA dossier for marketing approval of NS002 (intended Q2 2027).
• Pursue partnering opportunities for further development of NS001.
• Explore regulatory approval of products outside the United States (e.g., European scientific advice).
• Develop additional pipeline programs for other indications (Intranasal Midazolam, Atropine, Ondansetron).
• Remediate identified material weaknesses in internal control over financial reporting.
• Appoint an internal auditor within 90 days following the IPO.
• Obtain directors and officers liability insurance up to $25,000,000 upon completion of the offering.
• Obtain shareholder approval for the subcontractor agreement with Formulex prior to IPO closing.

Key Dates

Recommendation

The company is at a critical clinical stage with promising preliminary data for its intranasal drug delivery platform, particularly for NS002 (Epinephrine). The identified market opportunities for emergency medical conditions are substantial. However, the company faces significant financial challenges, including accumulated losses, a working capital deficit, and a going concern warning, indicating a high-risk investment. While the IPO aims to provide necessary funding, it's explicitly stated that these proceeds will not be sufficient for full commercialization, necessitating further capital raises. The pausing of NS001 development and unresolved contractual disputes with key suppliers add further uncertainty. A 'hold' recommendation is appropriate for seasoned investors who might already have exposure or are considering a speculative position, acknowledging the high risk-reward profile. It suggests waiting for more definitive clinical outcomes, successful remediation of financial control weaknesses, and clearer paths to commercialization and sustained funding before considering a 'buy' or 'sell.'

Keywords

intranasal drug delivery, epinephrine, anaphylaxis, naloxone, opioid overdose, powder-based technology, clinical stage, pharmaceutical development, IPO, biotechnology, FDA approval, clinical trials, drug formulation, medical emergencies, Israel, NYSE American